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ABSTRACT
Medication compliance may be a surrogate for factors that improve health outcomes such as fractures. Little is known about the size of
this potential ‘‘healthy adherer’’ effect. We evaluated the hypothesis that compliance with placebo is associated inversely with bone loss
and fractures among women participating in the Fracture Intervention Trial (FIT). Compliance with placebo and alendronate was
evaluated using daily medication diaries. Women were defined as having high compliance if they took 80% or more of dispensed study
medication. Change in bone mineral density (BMD) was assessed using mixed models comparing women with high versus lower
compliance with placebo. Cox proportional-hazards models analyzed the association between placebo compliance and various types of
fractures. Among 3169 women randomized to placebo, 82% had high compliance. Compared with women with lower placebo
compliance, bone loss at the total hip was lower in compliant placebo-treated women ( 0.43%/year versus  0.58%/year, p¼.04).
Amongplacebo-treatedwomen,therewere46hip,110wrist,77clinicalvertebral,and492totalclinicalfractures.Comparedwithwomen
with lower placebo compliance, women with high placebo compliance had a nonsignificant reduced risk for hip fracture [adjusted
hazard ratio (HR)¼0.67, 95% confidence interval (CI) 0.30–1.45]. This trend was not observed for other fractures. Medication compliance
maybea proxy forfactors thatconfers benefitonreducing hipfracture (butnot other types offractures) independentof the effect ofthe
medication itself. Nonrandomized studies of interventions designed to maintain or improve bone density and/or hip fracture may need
to consider medication compliance as a confounder to better estimate true intervention effects.  2011 American Society for Bone and
Mineral Research.
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Introduction
S
everal studies have reported a strong inverse relation
between high compliance with oral bisphosphonates and
fracture risk.
(1–5) A recent review has summarized many of
these studies and shown that long-term compliance with oral
osteoporosis medications generally is low and that women with
highcompliance who took atleast80%ofprescribed medication
had a substantially lower risk for fracture than less compliant
women.
(6) However, concerns have been raised that medication
compliance itself is associated with factors that may have a
favorable impact on outcomes. This finding, sometimes called
the ‘‘healthy adherer effect,’’ is apotential source of confounding
that is not always accounted for in analyses. Data supporting the
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683importance of the healthy adherer effect come from several
sources, including a meta-analysis of eight clinical trials showing
that high compliance with placebo was associated with a 44%
lower rate of death.
(7) High compliance also has been associated
with health-seeking behavior, use of preventive services (eg,
immunization and cancer screening tests), and a lower rate of
traumatic accidents.
(8,9) However, the existence and magnitude
of the healthy adherer effect has not been examined previously
with respect to fracture outcomes.
The Fracture Intervention Trial (FIT) was a trial that was
conducted in 11 US communities in the 1990s, included over
6000 women, and tested the efficacy of alendronate in
improving bone mineral density (BMD) and reducing fracture
risk.
(10–12) We used data from the FIT to evaluate the hypothesis
that high compliance with placebo was associated with lower
rates of bone loss and fracture. We also evaluated changes in
compliance following a fracture, hypothesizing that women
would be more likely to be noncompliant following a fracture.
Methods
Study population
The FIT was a placebo-controlled, double-blind trial of 6469
womenrandomizedtoalendronateversusplacebo.
(10,11)TheFIT-
IandFIT-IIcohortsincludedwomenwithlowbonemass(defined
as a T-score of less than  1.6 at the femoral neck) with and
without existing vertebral fracture at baseline, respectively. Data
from both groups of women were pooled for this analysis given
comparable compliance to study medication in the two cohorts.
Daily calcium intake was estimated by food-frequency ques-
tionnaire, and participants in both groups who had calcium
intakes of less than 1000mg were given a daily supplement
providing 500mg of elemental calcium (as the carbonate salt)
and 250 IU of cholecalciferol (vitamin D). About 82% of
participants received the supplement at the randomization visit.
Ascertainment of compliance and fracture outcomes
Compliance in FIT was evaluated using daily patient diaries and
pill counts returned at annual study visits, which had excellent
agreement with one another. Although compliance therefore
was defined as a continuous variable ranging from 0% to 100%,
women were defined as having high compliance in this analysis
if they took 80% or more of dispensed medication, following
prior conventions.
(6) Fractures were confirmed centrally through
review of medical records, as per the FIT protocol.
Statistical analysis
Descriptive statistics were used to summarize demographics,
comorbidities, and BMD data comparing women with high
compliance versus others; for purposes of this analysis, all
women who did not meet criteria for high compliance were
categorized as having lower compliance (<80%). Compliance
was measured in a time-varying manner and measured
as average compliance since the beginning of the study.
Compliance with placebo was the primary independent variable
of interest; outcomes associated with compliance with alen-
dronate also were evaluated for comparative purposes. Cox
proportional-hazards models were used to estimate the
association between high compliance and hip, clinical vertebral,
and wrist fractures. Change in BMD, reported as annualized
percent change, was assessed between study annual visits and
was analyzed in relation to compliance during this same interval
using mixed models. Each patient could contribute multiple
observations to the BMD analysis. Factors hypothesized to
potentially affect the association between compliance and
fractures (eg, age, fracture history, self-reported health status)
and baseline BMD were adjusted for in both the survival models
and the mixed models.
To better understand the dynamic nature of compliance in the
setting of an acute fracture, compliance was reported among
patients with hip, clinical vertebral, and wrist fracture, comparing
compliance before fracture (ie, from the beginning of the study
until the fracture date) with compliance after fracture (ie, from
the fracture dateuntil the end ofthe study). Agreement between
pre- and postfracture compliance was quantified using Cohen’s
kappa statistic with 95% confidence intervals (CIs). All analyses
were conducted using SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
A total of 3169 women participating in FIT were randomized to
placebo. Compliance with the placebo study medication was
high over the course of FIT, with 80% to 85% of women having
high compliance over the 4 years of the study (Fig. 1). Stratifying
these women into high versus lower compliance at the end of
FIT, Table 1 describes their characteristics. Women with lower
compliance were more likely than highly compliant women to
have fair/poor self-reported health and to be current or former
smokers.
The association between compliance with placebo or
compliance with alendronate and change in BMD is shown
in Table 2. As shown, women with high compliance with
alendronate had a significantly greater increase in BMD at all
sites than those with lower compliance with alendronate or
placebo-treated women. Women with high compliance with
placebohadsignificantlylessBMDlossatthetotalhipthanthose
with lower compliance with placebo. A similar pattern was
observed at the femoral neck but not the lumbar spine.
Fig. 1. Compliance over the course of FIT. Data shown are the percent of
women compliant at each time point.
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with placebo and fracture. Women with high compliance with
placebo had proportionately fewer hip fractures than those with
lower compliance with placebo. The adjusted rate of hip fracture
among women with high placebo compliance was 33% lower
than among women with lower placebo compliance, but
there were few events, and the results did not reach statistical
significance. There was no suggestion of an association between
high compliance with placebo and a reduced risk for any other
type of fracture. Comparing women with lower versus high
compliance with alendronate, there was an approximately 50%
lower risk for hip and clinical vertebral fracture among women
with high compliance with alendronate than among those with
lower compliance with alendronate.
Table 4 shows the adjusted risk of fracture comparing
alendronate versus placebo among those with both lower and
high compliance. Among women with lower compliance with
placebo or alendronate, there were no significant differences
between the two groups in the rates of any fracture type.
In contrast, among women with high alendronate compliance,
there was an adjusted and significant 45% lower risk for hip
fracture, a59%lower riskforclinical vertebral fracture, and a20%
Table 1. Baseline Characteristics of FIT Participants Randomized to Placebo (n¼3169)
Variable High compliance
a Lower compliance
a p Value
Age, % .49
<65 years 51.7% 51.0%
65–74 years 29.8% 28.1%
75–81 years 18.5% 20.8%
Mean (SD) age in years 68.2 (6.10) 68.6 (6.2) .12
Femoral neck, SDs below peak, % .90
>2.5 42.7% 42.5%
2.0–2.5 26.1% 27.1%
1.5–2.0 31.1% 30.4%
Mean (SD) BMD in g/cm
2
Femoral neck 0.58 (0.06) 0.58 (0.07) .26
Posteroanterior spine 0.83 (0.14) 0.82 (0.13) .54
History of fractures   45 years, % 41.9% 43.5% .49
Vertebral fractures at baseline, % 9.0% 9.9% .53
Body mass index, mean (SD), kg/m
2 25.2 (4.1) 25.4 (4.3) .26
Self-rated health status, % <.001
Very good/excellent 66.0% 54.5%
Good 29.6% 36.4%
Fair/poor 4.5% 9.1%
Baseline height, mean (SD), cm 1601 (61) 1599 (62) .64
Dietary calcium intake, mean (SD), mg/d 629 (395) 649 (399) .77
Smoking, % .03
Current 10.6% 13.3%
Former 34.0% 37.2%
Never 55.4% 49.5%
Note: For this table, compliance was assessed at the end of the study. All other compliance analyses were time-varying. Data were analyzed using chi-
square tests for nominal groups and t tests for continuous data.
aHigh compliance defined as 80% or greater; lower compliance defined as less than 80%.
Table 2. Annualized Percent Change in BMD of High and Lower Compliance With Placebo and Alendronate
Placebo Alendronate
Lower compliance High compliance Lower compliance High compliance
Total hip  0.58
a,b  0.43
a  0.30
a 0.99
Femoral neck  0.30
a,c  0.16
a  0.05
a 1.15
Spine 0.49
a,c 0.48
a 0.79
a 2.33
Note: Results are adjusted for age, baseline BMD, height, BMI, self-reported health, smoking status, calcium intake, calcium supplement use, having a
broken bone after age 45, and having a vertebral fracture at baseline.
ap<.0001 compared with alendronate high-compliance group.
abp¼.04 compared with placebo high-compliance group.
bcp¼NS compared with placebo high-compliance group.
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placebo compliance.
Compliance with study medication (placebo or alendronate)
before and after hip, clinical vertebral, and wrist fracture among
patients who fractured during the course of FIT is shown in
Table 5. Although most women had high compliance both
before and after fracture, women were more likely to change
from having high compliance before fracture to lower
compliance after fracture. For hip fractures, for example, 12
women who had high compliance prior to the hip fracture had
lower compliance following the fracture. No women with lower
compliance prior to hip fracture became highly compliant after
Table 3. Risk of Hip, Clinical Vertebral, Wrist, and All Clinical Fractures Comparing High Versus Lower Compliance With Placebo and
Alendronate
Placebo Alendronate
Fracture type Lower compliance High compliance Lower compliance High compliance
Hip, n 83 8 1 0 2 0
Crude rate
a 5.0 3.6 6.3 1.9
Crude HR 1.0 (referent) 0.67 (0.3–1.45) 1.0 (referent) 0.30 (0.14–0.63)
Adjusted
b HR 1.0 (referent) 0.67 (0.30–1.45) 1.0 (referent) 0.46 (0.19–1.10)
Clinical vertebral, n 10 67 11 31
Crude rate
a 6.3 6.4 6.9 2.9
Crude HR 1.0 (referent) 0.99 (0.51–1.94) 1.0 (referent) 0.43 (0.22–0.87)
Adjusted
b HR 1.0 (referent) 1.05 (0.53–2.06) 1.0 (referent) 0.51 (0.24–1.09)
Wrist, n 11 99 14 91
Crude rate
a 7.0 9.5 8.6 8.7
Crude HR 1.0 (referent) 1.34 (0.72–2.50) 1.0 (referent) 0.94 (0.53–1.65)
Adjusted
b HR 1.0 (referent) 1.18 (0.63–2.23) 1.0 (referent) 1.05 (0.57–1.93)
Any clinical fracture, n 57 435 64 349
Crude rate
a 39.0 44.5 43.2 35.1
Crude HR 1.0 (referent) 1.11 (0.84–1.47) 1.0 (referent) 0.80 (0.61–1.04)
Adjusted
b HR 1.0 (referent) 1.06 (0.80–1.41) 1.0 (referent) 0.87 (0.65–1.15)
HR¼hazard ratio.
aPer 1000 person-years.
bAdjusted for age, baseline BMD, height, BMI, self-reported health, smoking status, dietary calcium intake, calcium/vitamin D supplement provided by
study, having a broken bone after age 45, and having a vertebral fracture at baseline.
Table 4. Risk of Hip, Clinical Vertebral, Wrist, and All Clinical Fractures Comparing Lower Compliance With Placebo Versus Alendronate
and High Compliance With Placebo Versus Alendronate
Lower compliance High compliance
Fracture type Placebo Alendronate Placebo Alendronate
Hip, n 81 0 3 8 2 0
Crude rate
a 5.0 6.3 3.6 1.9
Crude HR 1.0 (referent) 1.26 (0.50–3.18) 1.0 (referent) 0.52 (0.30–0.90)
Adjusted
b HR 1.0 (referent) 0.86 (0.31–2.37) 1.0 (referent) 0.55 (0.32–0.95)
Clinical vertebral, n 10 11 67 31
Crude rate
a 6.3 6.9 6.4 2.9
Crude HR 1.0 (referent) 1.11 (0.47–2.60) 1.0 (referent) 0.46 (0.30–0.70)
Adjusted
b HR 1.0 (referent) 0.87 (0.35–2.14) 1.0 (referent) 0.41 (0.26–0.65)
Wrist, n 11 14 99 91
Crude rate
a 7.0 8.6 9.5 8.7
Crude HR 1.0 (referent) 1.27 (0.57–2.79) 1.0 (referent) 0.92 (0.69–1.22)
Adjusted
b HR 1.0 (referent) 1.03 (0.45–2.33) 1.0 (referent) 0.92 (0.68–1.23)
Any clinical fracture, n 57 64 435 349
Crude rate
a 39.0 43.2 44.5 35.1
Crude HR 1.0 (referent) 1.11 (0.78–1.58) 1.0 (referent) 0.79 (0.69–0.91)
Adjusted
b HR 1.0 (referent) 0.97 (0.67–1.41) 1.0 (referent) 0.80 (0.69–0.92)
HR¼hazard ratio.
aCompliance measured in a time-varying way.
bAdjusted for age, baseline BMD, height, BMI, self-reported health, smoking status, dietary calcium intake, calcium/vitamin D supplement provided by
study, having a broken bone after age 45, and having a vertebral fracture at baseline.
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fracture for each of the three fracture types was good, with
kappas in the 0.65 to 0.73 range.
Discussion
Among women participating in FIT who were randomized
to placebo, we did not find significant associations between
compliance with placebo and fractures. However, we found that
high compliance with placebo was associated with reduced
total-hip bone loss, and a similar trend was observed for changes
in femoral neck BMD. Furthermore, compared with women with
lower compliance with placebo, the risk of hip fracture was 33%
lower among women with high compliance with placebo; this
relationship did not reach statistical significance and was not
observed for any other clinical fracture type. These findings
suggest that the effect of compliance with placebo on hip
BMD, and perhaps hip fracture risk, was not attributable to
confounding by the known fracture risk factors collected in FIT.
In total, our findings provide some support for the existence of
the healthy adherer effect in this population and suggest that
medication compliance may be a proxy for behaviors and/or
other factors that confer hip BMD (and possibly hip fracture)
benefit independent of the effect of the medication.
The possible protective effect on hip fracture may be
mediated at least in part by changes in BMD, recognizing that
the correlation between change in BMD and fracture benefit is
only modest.
(14) Comparing women with high versus lower
compliance with placebo, the annualized difference in change in
hip BMD between the two groups was  0.15%. To provide some
contextforthisdifference,thesechangesinBMDarecomparable
with differences in BMD among depressed women compared
with those without depressive symptoms
(15) and with the
magnitude of BMD loss among women using selective serotonin
reuptake inhibitors (SSRIs) compared with nonusers.
(16)
In analyses that evaluated the dynamic nature of compliance,
we observed that compliance varied before and after fractures.
At least in a randomized, controlled trial (RCT), the occurrence of
a clinical fracture would appear to affect subsequent adherence
with study medication, at least for some patients. This finding
also has been reported in observational data from a nonclinical
trial population.
(1) These results support the conclusion that
analyzing compliance in a manner that ignores the time-
dependent nature of adherence before and after fractures may
yield biased results.
If the healthy adherer effect is generalizable to a nonclinical
trial setting, our findings may have implications for future com-
parative effectiveness research (CER) of osteoporosis medica-
tions, at least for hip fracture outcomes. Analyses studying the
relative effectiveness of medications that require intravenous
administration (eg, zoledronic acid and denosumab) will need to
carefully consider how to choose the most valid comparator
groups. For example, patients receiving parenteral osteoporosis
agentsgivenbyahealthcareproviderconsistofamixofpatients
who would have variable degrees of compliance with oral
bisphosphonates. Comparing these patients with patients who
are highly compliant with oral bisphosphonates could yield
biased results because the compliant oral bisphosphonate users
may have better outcomes (including lower hip fracture risk) in
part owing to the healthy adherer effect. In contrast, a com-
parator group of patients starting oral bisphosphonates, without
considering whether they remained compliant, would be biased
given their lesser exposure to bisphosphonates. These studies
could, for example, consider compliance with other medications
to at least partially address these concerns. Future work evalua-
ting healthy behaviors and factors that are associated with
compliance behavior are necessary to ensure unbiased results
from observational comparative effectiveness analyses.
Although our results suggested a trend toward reduced hip
fracture risk associated with placebo compliance, we did not
observe similar trends for other fracture types, such as wrist or
clinical vertebral fractures. Risk factors for wrist fractures are
different from those for hip fractures,
(17) and wrist fractures
generally occur in younger, healthier, and more active women.
Factors associated with medication adherence may be more
relevant for older, frailer patients at risk for hip fracture. Given
that our crude and fully adjusted results were similar for each
analysis, it would seem that the risk factors controlled for within
this analysis are not important confounders of fracture risk
associatedwithmedicationadherence.Furthermore,studiesthat
show a fracture benefit associated with medication compliance
may not be confounded if fracture types other than hip fractures
are being evaluated.
The strengths of our study include a large population of
women with median follow-up of more than 4 years. Fracture
outcomes were adjudicated through medical record review, and
longitudinal BMD data were available over the course of FIT.
Compliance was assessed with high precision through the use of
both patient diaries and pill counts. Despite these strengths, our
results must be interpreted in light of some limitations. Modest
numbers of outcome events and generally high compliance
Table 5. Comparison of Compliance With Study Medication (Alendronate or Placebo) Measured Before and After Fracture
Fracture type
High compliance
before and
after fracture
Lower compliance
before and
after fracture
High compliance before,
lower compliance
after fracture
Lower compliance
before, high
compliance
after fracture
Agreement
a between high
compliance at time
of fracture versus
end of study
Hip 53 11 12 0 0.66 (0.47–0.85)
Clinical vertebral 90 17 10 2 0.65 (0.49–0.81)
Wrist 182 21 10 2 0.73 (0.60–0.86)
Note: High compliance was 80% or greater; lower compliance was less than 80%.
aReported as kappa (95% CI); kappas between 0.60 and 0.80 are generally considered as ‘‘good agreement’’ (Altman et al., 1991).
(13)
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wide confidence intervals for some of our results. Additionally,
FIT was a clinical trial of women who were enrolled to study
fracture outcomes, and thus these results may not be general-
izable to other settings and patient populations. Last, some
factors that may affect fracture risk were not collected in FIT,
such as exercise, falls, depression, comorbidities, and measures
of frailty. The association between compliance and smoking and
poorer health status reported in Table 1 suggest the possibility
that these two factors may be proxies for one or more of
unmeasured confounders.
Another potentially important factor that was not system-
atically measured in FIT was 25-hydroxyvitamin D. An ancillary
study to FIT that sampled 1000 women at baseline showed that
only a small proportion (2.3%) were deficient in vitamin D
[25(OH)D   10ng/mL) at baseline, and the response to alen-
dronate was not affected by baseline 25(OH)D status.
(18)
However, it is unknown whether low vitamin D at baseline or
throughout the study might be associated with low compliance
and could have affected for our results.
In conclusion, based on these data from a randomized,
controlled trial, we found small but significant differences in the
change in hip BMD between women with high versus low
compliance with placebo. However, perhaps most important,
studies reporting fracture risk reduction associated with high
compliance with bisphosphonates do not appear to be
confounded by healthy behaviors and factors associated with
medication compliance except possibly for hip fracture. Further
workisneededtoassesstheexistenceofahealthyadherereffect
for fracture outcomes in other populations and how best to
control for this potential confounder.
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